AstraZeneca

X-Chem achieves milestones, licenses drug discovery programs to AstraZeneca

Wednesday, September 25, 2013 02:43 PM

X-Chem, a privately-held biotechnology company focused on applying its drug discovery capabilities to the generation of novel small molecule therapeutics, has achieved several milestones leading to the licensing of three drug discovery programs by AstraZeneca, in the context of a collaboration the companies established in May 2012.

More... »

AstraZeneca, Daiichi Sankyo launch reflux esophagitis iPhone app

Wednesday, September 18, 2013 01:36 PM

Daiichi Sankyo and AstraZeneca are working to educate the public about reflux esophagitis through a campaign entitled Do you experience heartburn or acid reflux? The awareness building effort seeks to ensure an accurate understanding of the symptoms of reflux esophagitis and how they affect the daily lives of patients. The campaign incorporates a variety of media, featuring TV commercials, an iPhone app and a website to encourage patients to seek the appropriate treatment and take control of their lives.

More... »

AstraZeneca, Merck enter license agreement for cancer

Wednesday, September 11, 2013 01:43 PM

AstraZeneca and Merck have announced a worldwide licensing agreement for Merck’s oral small molecule inhibitor of WEE1 kinase, MK-1775, currently being evaluated in phase IIa clinical studies in combination with standard of care therapies for the treatment of patients with certain types of ovarian cancer.

More... »

Otsuka to acquire Astex Pharmaceuticals

Friday, September 6, 2013 03:00 PM

Otsuka Pharmaceuticals will acquire Astex Pharmaceuticals for approximately $886 million, through a tender offer for all outstanding Astex shares expected to close in the fourth quarter.

More... »

Ambrx names Peter Kiener chief scientific officer

Wednesday, August 28, 2013 02:42 PM

Ambrx, a clinical stage biopharmaceutical company, has appointed Peter Kiener, Ph.D., chief scientific officer. Kiener has experience in the development of next-generation biologic therapeutics, including multi-specific, antibody based biologics, while president, chief executive officer and cofounder of Zyngenia.

Kiener led Zyngenia through its early stages of development, including validating the technology platform, identifying and advancing lead programs and securing Series A funding. Previously, Kiener was the executive vice president and global head of biologics R&D at MedImmune, AstraZeneca's biologics arm. He built protein and antibody engineering capabilities and oversaw the submission of multiple INDs and NDAs. Over the previous 18 years, Kiener held multiple positions at Bristol-Myers Squibb, 10 of which were spent working on biological therapeutics.

More... »

MedImmune acquires Amplimmune

Monday, August 26, 2013 12:24 PM

AstraZeneca has announced that MedImmune, its global biologics R&D arm, has agreed to acquire Amplimmune, a privately-held, Maryland-based biologics company focused on developing novel therapeutics in cancer immunology.

More... »

Ashfield names Michael Burman VP Medical Call Center

Monday, August 19, 2013 08:48 AM

Ashfield, part of United Drug, has named Dr. Michael Burman vice president of its Ivyland, Pa-based Medical Call Center. Ashfield Medical Information, formerly Alliance Healthcare, is a provider of medical information and pharmacovigilance call center services to healthcare, biotech and device companies.

More... »

AstraZeneca, FibroGen collaborate to develop and commercialize FG-4592

Wednesday, July 31, 2013 11:51 AM

AstraZeneca and biotechnology company FibroGen have entered into a collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD), which also may be extended to other anemia indications.

More... »

AstraZeneca selects Dotmatics platform

Monday, July 29, 2013 01:25 PM

AstraZeneca’s Neuroscience Innovative Medicines Unit (iMed) has selected Dotmatics’ cloud based informatics platform as its research data management solution. The Dotmatics platform provides a single point of access to all data and functions across multidisciplinary groups. The platform includes compound registration and tracking, biological screening, DMPK analysis, fully integrated chemistry and biology ELN and project management to enable scientists, collaborators and partners to instantly interact with the same data regardless of location and time zone.

More... »

Verified Clinical Trials partners with SAFE-BioPharma

Friday, July 26, 2013 09:00 AM

Verified Clinical Trials, whose technology helps eliminate multiple enrollments by clinical trial volunteers and provides Medicare Secondary Payer Law compliance strategies, will offer its services with SAFE-BioPharma, a global digital identity management and signature standard used by many of the world’s largest biopharmaceutical companies. The company also has joined the SAFE-BioPharma Vendor Partner program, providing it with direct access to decision-makers in SAFE-BioPharma’s member companies.

More... »